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Abstract
Background: Systemic inflammation might cause neuronal damage and sustain neurodegenerative diseases and
behavior impairment, with the participation of pro-inflammatory cytokines, like tumor necrosis factor (TNF)-α and
interleukin (IL)-18. However, the potential contribution of these cytokines to behavioral impairment in the long-term
period has not been fully investigated.
Methods: Wistar rats were treated with a single intraperitoneal injection of LPS (5 mg/kg) or vehicle. After 7 days
and 10 months, the animal behavior was evaluated by testing specific cognitive functions, as mnesic, discriminative,
and attentional functions, as well as anxiety levels. Contextually, TNF-α and IL-18 protein levels were measured by
ELISA in defined brain regions (that is, frontal cortex, hippocampus, striatum, cerebellum, and hypothalamus).
Results: Behavioral testing demonstrated a specific and persistent cognitive impairment characterized by marked
deficits in reacting to environment modifications, possibly linked to reduced motivational or attentional deficits.
Concomitantly, LPS induced a TNF-α increase in the hippocampus and frontal cortex (from 7 days onward) and
cerebellum (only at 10 months). Interestingly, LPS treatment enhanced IL-18 expression in these same areas only at
10 months after injection.
Conclusions: Overall, these results indicate that the chronic neuroinflammatory network elicited by systemic
inflammation involves a persistent participation of TNF-α accompanied by a differently regulated contribution of IL-
18. This leads to speculation that, though with still unclear mechanisms, both cytokines might take part in long-
lasting modifications of brain functions, including behavioral alteration.
Keywords: Neuroinflammation, Lipopolysaccharide (LPS), Behavioral impairment, Cytokines, Hippocampus, Frontal
cortex, Cerebellum
Background
The impact of systemic inflammation on the pathogen-
esis of chronic brain diseases, such as neurodegenerative
diseases, is a current and challenging topic of biomedical
research [1,2]. Pro-inflammatory cytokines, which have
effects on both immune and nervous systems, are cen-
tral players of inflammation and may contribute to brain
changes during both physiological and pathological pro-
cesses. As key mediators of a chronic neuroinflammation
that drives progressive tissue damage in the brain, cyto-
kines could take part to the pathogenesis and progres-
sion of neurodegenerative diseases [3-5]. However, a
better understanding of brain cytokine role in behavioral
and cognitive performances following systemic inflam-
mation, especially in the longer term after inflammatory
insults, remains an important area of research. Periph-
eral injection of the bacterial endotoxin component lipo-
polysaccharide (LPS) that models systemic infection, has
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been widely used to induce neuroinflammation, since it
results in the early brain synthesis of inflammatory cyto-
kines, such as interleukin (IL)-1β, IL-6, and tumor ne-
crosis factor (TNF)-α [6-8]. These inflammatory
mediators, in turn, appear central in driving behavioral
modifications, as in the case of the behavioral responses
to LPS, known as sickness behavior, which is the acute
consequence of cytokine elevation [9]. Notably, endo-
toxin triggering can also induce protracted behavioral
effects, as occurring in aging rats [10,11], as well as in
animal models of prion-disease [12,13] and amyotrophic
lateral sclerosis [14], where progression of symptoms
and neurodegenerative processes are persistently exacer-
bated after LPS treatment.
Differently, investigations in healthy adults aimed at
determining whether a single event of systemic inflam-
mation can as such induce long-lasting modifications of
behavior and brain cytokine synthesis are still limited.
Remarkably, two studies have been previously addressed
to investigate this issue in rodent models. A single LPS
administration results in delayed loss of neurons and
cholinergic innervations, leading to enduring behavioral
alterations characterized by memory deficits and
changes in exploratory patterns [15]. Moreover, TNF-α
appears to convey inflammation from periphery to brain,
where it is early and persistently released after LPS treat-
ment and causes microglia activation and significant loss
of neurons between 7 and 10 post-treatment months
[16]. Thus, it is predictable that additional cytokines
could take part to neuroinflammatory phenomena lead-
ing to chronic progression of neurodegeneration. Not-
ably, the pro-inflammatory cytokine IL-18 has recently
emerged as a key player in neuroinflammatory and neu-
rodegenerative processes, with wide behavioral and cog-
nitive effects [17-19]. However, the time-dependent
modifications of IL-18 expression within specific brain
regions after a peripheral neuroinflammatory event have
not yet been delineated.
The present research is aimed at characterizing the
long-term consequences of systemic inflammation on
behavioral/cognitive performances and brain cytokine
changes. To this aim, analyses of motivational, spatial,
mnesic, discriminative, and attentional functions, as well
as regional brain level measurements of the two cyto-
kines TNF and IL-18 were performed at 7 days and




Fifty adult male Wistar rats (weighing 200 g at the be-
ginning of the experiments; Harlan, Italy) were used.
The animals were pair-housed and kept under standard
conditions with food and water ad libitum on a 12/12 h
dark/light cycle (light on between 07:00 and 19:00 h).
The animals belonging to the LPS-treated group (LPS,
n= 26) were intraperitoneally (i.p.) injected with a single
dose of LPS from E. coli, strain 055:B5 (5 mg/kg; Sigma,
Italy) in 0.5 mL of volume, according to Qin and collea-
gues [16]. The animals belonging to the control group
(CTR, n= 24) were i.p. injected with 0.5 mL of vehicle
(sterile endotoxin-free PBS, Life Technologies, Italy). To
avoid potential influence of behavioral testing on cyto-
kine levels, cytokine assessment and behavioral testing
were performed on different animals. Thus, 26 rats (LPS,
n= 14; CTR, n= 12) were subjected to behavioral evalua-
tions, while 24 animals (LPS, n= 12; CTR, n= 12) under-
went brain cytokine analyses (Figure 1). Behavioral
testing and cytokine analyses were performed after LPS
challenge at two time-points, representative of long-term
responses in its early (7 days) and late (10 months)
phases.
Following i.p. injections, animals were observed for
the first 4 h and the presence of sickness behavior was
evaluated in all animals by measuring changes in body
weight and temperature. In addition, presence of piloer-
ection and lethargy was observed for 1 min at five post-
treatment time-points (0, 1, 2, 3, and 4 h). LPS injections
induced significant body weight loss (one-way ANOVA:
F1,48 = 7.1, P <0.01) and body temperature increase
(F1,48 = 4.01, P <0.05). The number of animals showing
lethargy and piloerection progressively increased as the
LPS post-injection hours went by, as indicated by Chi-
square test. Namely, in LPS animals the presence of
piloerection became significant from the first hour on-
ward and the presence of lethargy from the second hour
onward (χ2 = 6.0; d.f. = 1; P <0.01).
According to other authors [16], an increased level of
serum TNF-α was observed in treated animals at 4 h
after LPS treatment (186.6 ± 37.5 pg/mL; mean ± SE),
whereas in CTR rats this cytokine level was low and un-
detectable under our experimental conditions. At differ-
ence, serum IL-18 was undetectable in both LPS and
CTR animals.
Behavioral assessment
The behavioral assessment lasted two days and consisted
of three tests: Elevated Plus Maze, Open Field with
Objects, and Morris Water Maze.
Elevated plus maze (EPM)
The EPM raised 90 cm above the ground was formed by
a wooden structure in the shape of a cross with four
arms (50 cm× 10 cm). The north and south arms were
opened, while the east and west arms were enclosed by
36-cm-high walls. The rat placed on the central platform
was allowed to explore the maze for 5 min. The total
time spent in the open and close arms was measured.
Bossù et al. Journal of Neuroinflammation 2012, 9:101 Page 2 of 12
http://www.jneuroinflammation.com/content/9/1/101
Open field with objects (OF)
The apparatus consisted of a circular arena (diameter
140 cm) delimited by a 30-cm-high wall. During session 1
(S1), each rat was allowed to freely move in the empty
open field and its baseline activity level was measured.
During the habituation phase (S2-S4), four objects were
placed in a square arrangement in the middle annulus of
the arena and a fifth one was placed in the central area.
The five objects were: (1) a metal bar with a conical base;
(2) a plunger; (3) a long steel rod; (4) a yellow rubber plug;
and (5) a black cylinder with a plastic cup turned upside
down on top of it. During the spatial change (S5 and S6),
the spatial configuration was changed by moving objects 2
and 5 so that the initial square arrangement was modified
to a polygon-shaped configuration, without any central ob-
ject. During the novelty session (S7), the configuration was
modified by substituting object 4 with a green plastic ob-
ject shaped like a half moon. All sessions lasted 6 min; in-
ter-session intervals lasted 3 min. Rats’ behavior was
recorded by a video camera whose signal was relayed to a
monitor and to an image analyzer (Ethovision, Noldus,
Wageningen, The Netherlands).
In S1 the following motor and emotional parameters
were analyzed: total distance (in cm) traveled in the
arena; percentage of distances traveled in a 20-cm per-
ipheral annulus; number of central crossings; motionless
time; number of defecation boluses. In S2-S4 total time
spent in contacting object was analyzed. Contact was
considered to have taken place when the rat’s snout ac-
tually touched an object or when it sniffed the object for
at least 1 s, but not when the rat leaned against, stood,
or sat on the object. In S5-S7 the time spent contacting
objects was expressed as discrimination index (d index),
that is time exploring displaced (or novel) objects minus
time exploring not displaced (or familiar) objects/total
exploration time.
Morris water maze (MWM)
The rats were placed in a circular white pool (diameter
140 cm) filled with 24°C water made opaque by the
addition of a-toxic acrylic color (Giotto, Italy). An escape
platform (diameter 10 cm) was submerged 2 cm below
the water level. Each rat was submitted to two consecu-
tive phases (Place and Probe) consisting of eight trials
(Place) and one trial (Probe). During Place, the rat
released into the water from randomly varied starting
points was allowed to find the hidden platform for a
maximum of 120 s. When the rat reached the platform,
it was allowed to remain there for 30 s. The inter-trial
interval was 3 min. Then, the platform was removed and
rats were allowed to swim for 60 s in searching for it
(Probe phase). Rats’ navigational trajectories were
recorded by a video camera whose signal was relayed to
a monitor and to the previously described image
analyzer. In analyzing MWM performances the following
behavioral parameters were considered: latencies to find
the platform; total distances swum in the pool; mean
swimming velocity; percentage of time spent in the
rewarded quadrant (presence of platform) in the Probe
phase; navigational strategies put into action in reaching
the platform. The navigational strategies were classified
in five main categories [20], regardless the platform was
reached or not: Circling (C), that is, swimming in a 20-


































Figure 1 Experimental design. Fifty adult male Wistar rats were intraperitoneally injected with either LPS (5 mg/kg in 0.5 mL) or PBS (0.5 mL).
The 26 animals subjected to behavioral evaluations were divided into two groups (LPS, n= 14; CTR, n= 12) which were used for Elevated Plus
Maze (EPM), Open Field with Objects (OF), and Morris Water Maze (MWM) assessments, respectively, at 7 days and 10 months following LPS or
PBS injections. The remaining 24 animals that underwent brain cytokine analyses were divided into two groups (LPS, n= 12; CTR, n= 12) for the
measurement of regional TNF-α and IL-18 levels at 7 days and 10 months following LPS or PBS injections.
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direction and counterclockwise and clockwise turnings
in the peripheral sector of the pool; Extended Searching
(ES), that is, swimming around the pool in all quadrants,
visiting the same areas more than once; Restricted
Searching (RS), that is, swimming in some pool quad-
rants, not visiting some tank areas at all; Restricted Circ-
ling (RC), that is, reaching the platform by swimming
only in the peripheral annulus; direct Finding (F), that is,
swimming towards the platform without any foraging
around the pool. Two researchers who were unaware of
the individual specimen’s group categorized the swim-
ming trajectories drawn by the image analyzer. They
attributed the dominant behavior in each trial to a spe-
cific category. Categorization was considered reliable
only when their judgments were consistent.
Assessment of protein levels of cytokines in serum and
brain tissue
For serum cytokine measurement, blood samples were
taken in terminally anaesthetized rats and collected in
microfuge tubes. Samples were spun down and serum
kept at −80°C until further use.
For brain cytokine measurement, rats were sacrificed by
decapitation and the brains were quickly removed and dis-
sected on ice using a binocular dissection microscope.
Frontal cortex, hippocampus, striatum, cerebellum, and
hypothalamus were dissected on ice by a trained researcher
according to Glowinski and Iversen’s method [21]. All brain
regions were extracted in 1 mL extraction buffer/100 mg tis-
sue. Brain tissue samples were homogenized in an ice-cold
lysis buffer containing 137 mM NaCl, 20 mM Tris–HCl
(pH 8.0), 1% NP40, 10% glycerol, 1 mM PMSF 10 μg/mL
aprotinin, 1 μg/mL leupetin, and 0.5 mM sodium vanadate.
The tissue homogenate solutions were centrifuged with
14000× g for 25 min at 4°C. The supernatants were col-
lected and stored at −80°C until analysis.
Quantification of serum and intracerebral TNF-α and
IL-18 protein levels were assessed by ELISA kit (Bio-
source, Invitrogen), according to manufacturer’s instruc-
tions. The limit detection of assays was 4 pg/mL for TNF-
α and 15 pg/mL for IL-18. Cytokine results, reported as
picograms of the measured molecule per mL of serum
(pg/mL) or per gram of tissue (pg/g) are expressed as
mean values ± SEM. Where indicated, cytokine amounts
were also normalized to protein content. In this case, the
concentration of total protein in the brain extracts was
measured by Bradford assay (BioRad Laboratories).
Statistical analysis
The data were firstly tested for normality (Wilk-Shapiro’s
test) and homoscedasticity (Levene’s test). Then, they were
analyzed by one-way or two-way ANOVAs for independent
(treatment, time) and repeated (trial, session, arm) measures
followed by Tukey’s HSD test. Non-parametric data related
to piloerection and lethargy evaluation were analyzed by
means of a Chi-squared metric. The significance level was
established at P <0.05.
Ethical approval
The experimental research reported in this manuscript
has been performed with the approval of the Ethical
Committee on animal experiments of Fondazione Santa
Lucia and all efforts were made to minimize animal suf-
fering and to reduce their number, in accordance
with the European Community Council Directive of 24
November 1986 (86/609/EEC).
Results
Seven days following LPS treatment
EPM
No differences in anxiety levels were evident between
groups (Figure 2A). A two-way ANOVA (treatment x arm)
revealed that all animals spent more time in the close vs.
open arms (arm effect: F1,10= 141.68, P<0.001), without sig-
nificant treatment effect (F1,10=0.31, P n.s.) and interaction
(F1,10 =0.59, P n.s.).
OF
In S1, LPS rats traveled around the arena significantly less in
comparison to CTR (Figure 2, B1), while no significant treat-
ment effect was evident on peripheral distances and on the
number of central crossings (one-way ANOVAs: total dis-
tance: F1,10 =5.37, P <0.05; peripheral distance: F1,10 =0.86,
P n.s.; central crossings: F1,10= 1.32, P n.s.) (Figure 2, B2-3).
All animals exhibited comparable levels of anxiety as indi-
cated by the absence of significant differences between
groups in the number of defecation boluses and motionless
time (defecation boluses: F1,10 =0.01, P n.s.; motionless time:
F1,10= 1.52, P n.s).
In S2-S4, all animals showed habituation, progressively de-
creasing exploration time of objects (Figure 2, B4). A two-
way ANOVA (treatment x session) revealed a significant
session effect (F2,20= 9.93, P <0.05). Treatment and inter-
action effects were not significant (treatment: F1,10 =4.38, P
n.s.; treatment x session: F2,20=0.60, P n.s.).
In S5, while CTR rats detected the new spatial arrangement
and contacted displaced objects more than non-displaced
objects, LPS rats failed to detect the new spatial arrangement
(one-way ANOVA: F1,10=6.60, P <0.05) (Figure 2, B5). In S6,
while CTR rats no more reacted to the spatial change, LPS
rats persisted in not reacting to change (F1,10=0.91, P n.s.).
In S7, LPS rats failed to recognize the novel object.
Significant treatment effect was found on d index
(F1,10 = 6.59, P <0.05) (Figure 2, B6).
MWM
Place. No significant differences in reaching the hidden
platform were evident between experimental groups
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(Figure 2, C1-2). A two-way ANOVA (treatment x trial)
confirmed that all rats displayed a progressive latency re-
duction as trials went by (F7,70 = 15.47, P <0.001), without
significant treatment effect (F1,10 = 1.30, P n.s.), and inter-
action (F7,70 = 2.15, P n.s.). No differences were found in
the swimming velocities (LPS rats x : 21.70± 0.53 cm/s;
CTR rats x : 21.48±2.44 cm/s; one-way ANOVA:
F1,10 = 0.79, P n.s.) as well as in the total distances (two-way
ANOVA: treatment effect: F1,10 = 0.81, P n.s.; trial effect:
F7,70 = 30.09, P <0.001; interaction: F7,70 = 2.01, P n.s.). The
analysis of the navigational strategies did not reveal any dif-
ference between groups.
Probe. No relevant differences were evident between
experimental groups, as revealed by a one-way ANOVA
on the percentage of time spent in the previously
rewarded quadrant (F1,10 = 0.07, P n.s.) (Figure 2, C3).
Cytokine analysis
Figure 3 depicts the levels of TNF-α and IL-18 in frontal
cortex, hippocampus, cerebellum, striatum and hypo-
thalamus measured 7 days after LPS or PBS injections.
With regard to TNF-α (Figure 3, upper panels), its
levels were significantly higher in LPS vs. CTR animals
in hippocampus (one-way ANOVA: F1,10 = 6.81, P <0.05)
and in the frontal cortex (F1,10 = 17.12, P <0.01). No sig-
nificant differences in TNF-α levels were found between
LPS and control animals in cerebellum, striatum, and
hypothalamus.



















































































































Figure 2 Effects of i.p. injection of LPS on behavioral performances at 7 days post-treatment. (A) Mean time spent in the open and close
arms by the animals in Elevated Plus Maze is depicted. (B) Total distance (1), peripheral distance (2), central crossings (3), mean contact times with
objects during habituation phase (S2-S4) (4), spatial change (5), and novelty (6) exhibited by the two experimental groups in Open Field with
Objects are depicted. (C) Mean escape latencies to reach the platform (1), navigational strategies (2), and time spent in the rewarded quadrant (3)
displayed by the two experimental groups in Morris Water Maze are depicted. In this figure, the circular figurines illustrate the typical explorative
patterns of the five navigational strategies (C, Circling; ES, Extended Searching; RS, Restricted Searching; RC, Restricted Circling; F, direct Finding).
Asterisks inside the graphs indicate the significance of comparisons between groups: * P <0.05, *** P ≤0.001.
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IL-18 levels (Figure 3, lower panels) were in general
slightly more elevated in most brain regions of LPS, as
compared to CTR animals, but at variance with TNF-α,
the statistical significance was not reached in any of the
analyzed cerebral regions. However, a trend towards IL-
18 increase for LPS as compared to CTR rats was
observed in frontal cortex (526.0 ± 141.6 vs.
290.3 ± 64.73; P= 0.16). In this experiment, cytokine data
have been also calculated by normalizing to protein con-
tent instead than to tissue weight and very similar results
have been obtained with the two methods (not shown).
No detectable TNF-α and IL-18 levels have been found
in serum of both LPS and CTR animals.
Ten months following LPS treatment
EPM
The two experimental groups did not differ on anxiety
levels and all animals exhibited the standard open arms
avoidance (Figure 4A). A two-way ANOVA (treatment x
arm) indicated not significant treatment effect (F1,12 = 0.59,
P n.s.) and interaction (F1,12 = 0.10, P n.s.), while arm effect
was significant (F1,12 = 6.91, P <0.05).
OF
In S1, LPS rats traveled around the arena significantly less
in comparison to CTR animals (Figure 4, B1), although
significant differences between groups were not evident
on peripheral distances and number of central crossings
(one-way ANOVAs: total distance: F1,12 = 11.45, P <0.05;
peripheral distance: F1,12 = 1.77, P n.s.; central crossings:
F1,12 = 2.78, P n.s.) (Figure 4, B2-3). All animals exhibited
comparable levels of anxiety as indicated by the absence
of significant differences between groups in the number of
defecation boluses and motionless time (defecation
boluses: F1,12 = 0.58, P n.s.; motionless time: F1,12 = 2.47, P
n.s).
All animals habituated as the total amount of time
spent exploring the five objects decreased from S2 to S4
(session effect: F2,24 = 12.33, P< 0.001) (Figure 4, B4).
Treatment effect (F1,12 = 0.12, P n.s.) and interaction
(F2,24 = 0.31, P n.s.) were not significant.
In S5, differently from CTR, LPS animals did not detect
the spatial change (one-way ANOVA: F1,12 = 5.39, P
< 0.05) (Figure 4, B5). In S6, LPS rats did not still react to
the spatial change, while CTR animals stopped to react to
change (F1,12 = 0.71, P n.s.). Once more, in S7, when the
novel object was placed in the arena, LPS rats did not
recognize it (F1,12 = 21.65, P <0.001) (Figure 4, B6).
MWM
Place. No significant differences in reaching the hidden plat-
form were evident between groups (Figure 4, C1-2). A two-
way ANOVA (treatment x trial) revealed that both groups
displayed a progressive latency reduction as trials went by
(F7,84 =7.02, P <0.001), without significant treatment effect
(F1,12 =0.02, P n.s.) and interaction (F7,84= 1.21, P n.s.). No
differences were found in the swimming velocities (LPS x :
























































































Figure 3 Effects of i.p. injection of LPS on brain regional expression of cytokines at 7 days post-treatment. The levels of TNF-α (upper
row of panels) and IL-18 (lower row of panels) in LPS-treated (LPS, black bar) and PBS injected control animals (CTR, open bar) were assessed
7 days post-treatment by using specific ELISA, as described in the Materials and methods section. Results are reported as histograms representing
the cytokine mean concentrations with SEM error bars for each dissected brain region. Values measured from each group of rats (n= 6) were
calibrated by tissue weight. Asterisks inside the graphs indicate the significance of comparisons between groups: * P <0.05, ** P <0.01.
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ANOVA: F1,12= 0.17, P n.s.) as well as in the total distances
(two-way ANOVA: treatment effect: F1,12 =0.99, P n.s.; trial
effect: F7,84= 4.84, P <0.001; interaction: F7,84= 0.38, P n.s.).
Furthermore, no significant differences between groups were
observed on the navigational strategies.
Probe. A one-way ANOVA on the percentage of time
spent in the previously rewarded quadrant failed to reveal any
significant treatment effect (F1,12=0.20, P n.s.) (Figure 4, C3).
Cytokine analysis
The increase of TNF-α already observed in the earlier
post-treatment stage was maintained in the brain
regions of LPS versus CTR animals (Figure 5, upper
panels). In particular, the significant increase of TNF-α
was maintained in the frontal cortex (one-way ANOVA:
F1,10 = 8.16, P <0.05) and hippocampus (F1,10 = 9.91,
P <0.05) and reached in cerebellum (F1,10 = 11.86,
P = 0.01). Furthermore, not significant differences in
TNF-α levels were observed in striatum and
hypothalamus.
Alike to TNF-α, IL-18 levels were significantly more
elevated in LPS than CTR animals (Figure 5, lower
panels) in frontal cortex (F1,10 = 15.31, P <0.01), hippo-
campus (F1,10 = 33.46, P <0.001), and cerebellum
(F1,10 = 8.49, P <0.05). Again, no significant changes in
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Figure 4 Effects of i.p. injection of LPS on behavioral performances at 10 months post-treatment. (A) Mean time spent in the open and
close arms by the animals in Elevated Plus Maze is depicted. (B) Total distance (1), peripheral distance (2), central crossings (3), mean contact
times with objects during habituation phase (S2-S4) (4), spatial change (5), and novelty (6) exhibited by the two experimental groups in Open
Field with Objects are depicted. (C) Mean escape latencies to reach the platform (1), navigational strategies (2), and time spent in the rewarded
quadrant (3) displayed by the two experimental groups in Morris Water Maze are depicted. In this figure, the circular figurines illustrate the typical
explorative patterns of the five navigational strategies (C, Circling; ES, Extended Searching; RS, Restricted Searching; RC, Restricted Circling; F, direct
Finding). Asterisks inside the graphs indicate the significance of comparisons between groups: * P <0.05, *** P ≤0.001.
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At this time point serum TNF-α and IL-18 levels have
not been evaluated.
Discussion
Progressive neurodegeneration has been proposed to be
driven by chronic persistent inflammation, but up to
now the chronic neuroinflammatory processes poten-
tially implicated in neuronal damage leading to cogni-
tive impairment are scarcely detailed. In the present
study we show that a single peripheral inflammatory in-
sult induces persistent discriminative deficits accompan-
ied by different regional patterns of brain TNF-α and
IL-18 expression.
As early consequence of LPS treatment (7 days),
we observed a motor hypoactivity and discriminative
deficits (in OF) not associated to any spatial memory
deficit (MWM Probe trial results) or anxiety expres-
sion (in EPM and OF). In particular, LPS rats exhib-
ited marked discriminative deficits, when in OF
spatial arrangement and saliency of the objects were
changed. These results are in line with the impaired
object recognition described in mice 4 days after
LPS treatment [22].
These behavioral changes may be interpreted in
terms of reduced motivation resulting in reduced
responsivity toward the context. Noteworthy, reduced
motivation leading to diminished investigation of ju-
venile conspecifics in the social exploration has been
described in rodents at very early stage following LPS
treatment [23,24]. Nevertheless, it has to be underlined
that the lack of spatial change detection in LPS rats
might be ascribed also to an attentional deficit disrupt-
ing some, although not all, components of the spatial
information processing. This faceted behavioral pat-
tern, already encountered in the presence of choliner-
gic depletion, could be linked to the different stress
levels of MWM and OF tasks [25]. Actually, although
both tasks are hippocampal-dependent, MWM puts
forward attentional requests but involves high stress
levels given the forced swimming in the search of the
escape platform, while OF requires high attentional
load but in an experimental context not closely related
to survival and thus with lower stress levels. Thus, the
different findings observed in MWM and OF tasks
could be linked to the saliency of the MWM platform
higher than the mere spatial re-arrangement of OF
objects.
The late behavioral pattern (10 months) was similar to
that displayed 7 days after LPS injection. While no modi-
fication of spatial memory or anxiety levels was
observed, motor hypoactivity and discriminative deficits
were once again present, indicating that a systemic in-
flammatory response evoked by a single LPS injection
(5 mg/kg) is able to significantly affect cognitive func-
tions even 10 months later. These results are in line with

























































































BRAIN CYTOKINES (10 months)
Figure 5 Effects of i.p. injection of LPS on brain regional expression of cytokines at 10 months post treatment. The levels of TNF-α
(upper row of panels) and IL-18 (lower row of panels) in LPS-treated (LPS, black bar) and PBS-injected control animals (CTR, open bar) were
assessed 10 months post-treatment by using specific ELISA, as described in the Materials and methods section. Results are reported as histograms
representing the cytokine mean concentrations with SEM error bars for each dissected brain region. Values measured from each group of rats
(n= 6) were calibrated by tissue weight. Asterisks inside the graphs indicate the significance of comparisons between groups: * P <0.05,
** P <0.01, *** P <0.001.
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behavioral and cognitive impairment, neuronal loss in
frontal cortex and hippocampus, as well as reduced cho-
linergic innervation in parietal cortex occurring up to
3 months after treatment in a rat model of sepsis evoked
by high-dose LPS (10 mg/kg). Furthermore, two intraper-
itoneal LPS injections (500 μg/kg) at postnatal days 7 and
9 in rat pups caused reduced locomotor activity and defi-
cits in object recognition memory tested at day 70, as
well as decreased expression of parvalbumin immunor-
eactive neurons in the CA1-CA3 hippocampal regions
and no changes in frontal cortex [26].
It is to be considered that the explorative and discrim-
inative deficits found in the present study could be also
linked to a specific loss of dopaminergic neurons. In fact,
in experimental conditions similar to those of our study,
LPS progressively reduces the number of tyrosine hydro-
xylase-immunoreactive neurons in the substantia nigra
[16]. Interestingly, bilateral lesions of the pars compacta
of the substantia nigra elicit in rats impairment of object
recognition associated with microglial activation in the
hippocampus, but not in the striatum [27]. Taking into
account these observations, the long-term impairment
of exploratory and discriminative functions observed in
our LPS rats could be related to a reduced functionality
of either cholinergic [15] and dopaminergic [16] systems.
These two systems appear to be implicated the former
one in the attentional tuning controlling discriminative
behaviors [28,29] and the latter one in the locomotory
function and motivational drive to explore objects
[30,31].
As previously described, at the time-points chosen as
representative of early and late stages of long-term
LPS response, the analysis of the behavioral perfor-
mances has been matched by analysis of brain cytokine
expression. Interestingly, LPS treatment was able to
elevate the expression of TNF-α in definite brain
regions across the entire experimental period. In par-
ticular, since our first evaluation (7 days), TNF-α was
significantly elevated in the frontal cortex and in the
hippocampus and it remained significantly higher than
in CTR animals also at 10 months. In addition, TNF-α
levels were increased even in the cerebellum 10 months
after LPS treatment. These results are in line with a
previous study, where 2 months after peripheral LPS
administration, a TNF-α mRNA increase was observed
in the cortex and hippocampus, as well as cerebellar
structures [32].
The lack of neuroinflammatory reactions in the stri-
atum could be ascribed to the fact that either specific
neuronal subtypes and brain regions are susceptible to
inflammation more than others in relation to microglial
component [33,34]. Conversely, the unresponsiveness of
the hypothalamus to LPS insult could be attributed to
the late times analyzed in our study, given that after
systemic LPS administration a transient increase in
TNF-α, ranging from 1 to 3 to 18 h, has been previously
observed [6,35,36].
Intriguingly, IL-18 levels significantly increased in
frontal cortex, hippocampus, and cerebellum at the lat-
est (10 months), but not at the earlier (7 days) stage of
LPS-induced long-term neuroinflammation. On the
other hand, the very low levels of both TNF-α and IL-18
we observed in serum of treated animals 7 days after the
LPS treatment are in agreement with previous studies
describing that the circulating levels of pro-inflammatory
cytokines increase soon after the endotoxic insult, but
that after the acute response they subside in the blood,
while stay elevated in the brain [16]. Furthermore, these
results strongly suggest that in this study, the measured
TNF-α and IL-18 elevation in the brain is independent
from their concentration in the blood.
Therefore, according to their profile of expression, the
two cytokines seem to differently participate in brain in-
flammatory response. Regarding TNF-α, our results sup-
port and further expand the view that this cytokine is an
early and persistent mediator of the long-lasting inflam-
matory cascade [16]. In fact, TNF-α might have a pivotal
role in conveying inflammation from periphery to brain,
as primary stimulus that promotes self-propelling mech-
anism of microglial activation, induces persistent brain
production of pro-inflammatory cytokines including IL-
1β and, ultimately, leads to progressive neurodegenera-
tion. Differently from TNF-α, IL-18 might act as a
delayed mediator of neuroinflammation, in agreement
with data obtained in experimental models of brain is-
chemia and trauma [37,38].
Regarding the possible molecular mechanisms, while
quite a lot of evidence corroborates the hypothesis of an
involvement of brain TNF-α in neurodegeneration and
cognitive decline, even identifying some of its driving
mechanisms [16,39-43], much less data are available
about the molecular links between brain IL-18 expres-
sion and cognitive functions.
In line with our data, IL-18 has been previously found
constitutively expressed in the cortex, hippocampus,
cerebellum, hypothalamus, and striatum [44] and it is
also detectable in astrocytes and microglia after LPS
treatment [45,46]. However, by means of immunocyto-
chemistry analysis, other studies have shown, that IL-18
protein is mainly expressed in the neurons of the medial
habenula and in the ependymal cells surrounding the
lateral and the third ventricles, without significant stain-
ing in microglial cells or astrocytes [47]. Therefore, even
though microglia might be a relevant cellular source of
increased IL-18 in our experimental conditions, add-
itional studies should be performed to identify the IL-18
producing cells within the brain in the presence of LPS-
mediated long-term neuroinflammation. Although with
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some fluctuations, we observed the expression of IL-18
protein (both constitutive and LPS-induced) in the
brains of the rats analyzed both at 7 days and at
10 months. These data are in agreement with other
results showing that IL-18 is present in immature and
adult brain, as the cytokine is present in neonatal brain
in normal conditions and during hypoxic-ischemic brain
injury [48,49] and it is involved in neuronal cell death
during traumatic brain injury both in immature and
adult brain [38,50]. In fact, although this cytokine has
been generally associated with the amplification of age-
dependent inflammatory processes [51] and it may be
relevant in age-related functional impairment [52], its
role in CNS might be important in both health and dis-
ease since the development, throughout the whole life.
In neuroinflammatory conditions, given that brain cyto-
kines function as an integrated network [53], the increased
expression of IL-18, probably modulated by TNF-α itself
[54], could participate in perpetuating brain inflammation
by stimulating the activation of the transcription factor
NF-κB and the production of other pro-inflammatory
mediators, such as IL-1β and TNF-α [55,56]. As a conse-
quence, the increase of IL-18 expression in the brain
might influence progressive neurodegeneration and cogni-
tive dysfunction. In fact, in both experimental and clinical
settings, IL-18 appears to directly or indirectly interfere
with the processes of memory consolidation, synaptic
plasticity and/or neurogenesis [18,57-60]. Noteworthy, the
role of IL-18 in mediating the behavioral effects of LPS in-
jection observed in our conditions is supported by a re-
cent study showing that the expression of the IL-18
signaling receptor and of its short variant considered a po-
tential negative regulator of IL-18, is tightly modulated by
LPS and occurs in specific brain areas associated with the
limbic system [61].
Overall, in spite of the intriguing association between
behavioral/cognitive impairment and cytokine expres-
sion observed in the present research, we are aware that
the present data do not allow defining the causal role of
the increased TNF-α and IL-18 expression in behavioral
and cognitive abnormalities. Similarly, they do not allow
identifying at brain regional level the molecular mechan-
isms of chronic inflammatory network that could partici-
pate in long-term cognitive decline. Nonetheless, by
taking together other authors’ results and ours, it is pos-
sible to hypothesize that the peripheral administration of
high-dose LPS could cause TNF-α dependent activation
of microglia and subsequent increase of brain cytokines,
like TNF-α itself, IL-1β, and IL-18 [16, the present
paper] which might concur in inducing persistent behav-
ioral alterations [15, the present paper] probably caused
by a long-term loss of neurons [15,16]. In addition, LPS-
induced cytokine alterations may influence behavior by
affecting neurotransmitterial function, neuroendocrine
activity, neuronal plasticity properties and brain circuitry
[62], mechanisms and functions whose evaluation is be-
yond the scope of the present study. Thus, whether and
how a direct association between behavioral dysfunction
and brain cytokine elevation indeed exists remains an
open question.
Conclusions
The present study describes a persistent behavioral im-
pairment and a protracted and distinctive elevation of
brain TNF-α and IL-18 expression, as long-term conse-
quences of a single inflammatory insult occurred
10 months before. These observations appear to be im-
portant elements at the base of inflammation-induced
cognitive/behavioral impairment, suggesting that both
cytokines, although with a different pattern, might take
part in the enduring deterioration of behavioral func-
tions caused by systemic inflammation.
Furthermore, these findings support the recently
hypothesized participation of IL-18 in the progressive
neurodegeneration that occurs in some forms of
dementia.
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